HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Foos, G. Articles by Hauser, C. A. Search for Related Content PubMed PubMed Citation Articles by Foos, G. Articles by Hauser, C. A. Social Bookmarking                      What's this?

J Biol Chem, Vol. 273, Issue 30, 18871-18880, July 24, 1998

Elevated Expression of Ets2 or Distinct Portions of Ets2 Can Reverse Ras-mediated Cellular Transformation

From the La Jolla Cancer Research Center, The Burnham Institute, La Jolla, California 92037

Ets transcription factors are important downstream targets of oncogenic Ras. The transcriptional activity of several Ets family members is regulated by Ras, and interfering with Ets-dependent transcription by expression of just the Ets2 DNA binding domain can inhibit or reverse Ras-mediated cellular transformation. To better understand the role of Ets proteins in Ras transformation, we have now analyzed the effects of stably expressing a variety of Ets2 constructs in Ras-transformed NIH3T3 (DT) cells. Expression of only the Ets2 transactivation domains, which also inhibits Ras or Neu/ErbB-2-mediated activation of Ets-dependent transcription, strongly inhibited anchorage-independent growth, but did not revert the transformed DT cell morphology. Unexpectedly, high expression of full-length Ets2, a transcriptional activator, broadly reversed the transformed properties of DT cells, including anchorage-independent growth, transformed morphology, and tumorigenicity, but did not impair attached cell growth. Increasing full-length Ets2 transcriptional activity by fusing it to the VP16 transactivation domain enhanced its ability to reverse DT cell transformation. Mutational analysis revealed that the mitogen-activated protein kinase phosphorylation site required for Ras-mediated activation, Ets2(T72), was not essential for Ets2 reversion activity. The distinct reversion activities of the highly expressed Ets2 transactivation domains or full-length Ets2, along with the specific reversion activity by Ets2 constructs that either inhibit or activate Ets-dependent transcription, suggests multiple roles for Ets factors in cellular transformation. These results indicate that several distinct approaches for modulating Ets activity may be useful for intervention in human cancers.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				S. Kim, C. T. Denny, and R. Wisdom Cooperative DNA Binding with AP-1 Proteins Is Required for Transformation by EWS-Ets Fusion Proteins. Mol. Cell. Biol., April 1, 2006; 26(7): 2467 - 2478. [Abstract] [Full Text] [PDF]

				C.-d. Geng and W. V. Vedeckis c-Myb and Members of the c-Ets Family of Transcription Factors Act as Molecular Switches to Mediate Opposite Steroid Regulation of the Human Glucocorticoid Receptor 1A Promoter J. Biol. Chem., December 30, 2005; 280(52): 43264 - 43271. [Abstract] [Full Text] [PDF]

				R. N. Gunawardane, D. C. Sgroi, C. N. Wrobel, E. Koh, G. Q. Daley, and J. S. Brugge Novel Role for PDEF in Epithelial Cell Migration and Invasion Cancer Res., December 15, 2005; 65(24): 11572 - 11580. [Abstract] [Full Text] [PDF]

				S. W. Chung, Y.-H. Chen, and M. A. Perrella Role of Ets-2 in the Regulation of Heme Oxygenase-1 by Endotoxin J. Biol. Chem., February 11, 2005; 280(6): 4578 - 4584. [Abstract] [Full Text] [PDF]

				J. L. Kopp, P. J. Wilder, M. Desler, J.-H. Kim, J. Hou, T. Nowling, and A. Rizzino Unique and Selective Effects of Five Ets Family Members, Elf3, Ets1, Ets2, PEA3, and PU.1, on the Promoter of the Type II Transforming Growth Factor-{beta} Receptor Gene J. Biol. Chem., May 7, 2004; 279(19): 19407 - 19420. [Abstract] [Full Text] [PDF]

				C. K. Galang, W. J. Muller, G. Foos, R. G. Oshima, and C. A. Hauser Changes in the Expression of Many Ets Family Transcription Factors and of Potential Target Genes in Normal Mammary Tissue and Tumors J. Biol. Chem., March 19, 2004; 279(12): 11281 - 11292. [Abstract] [Full Text] [PDF]

				A. K. Man, L. J. T. Young, J. A. Tynan, J. Lesperance, M. Egeblad, Z. Werb, C. A. Hauser, W. J. Muller, R. D. Cardiff, and R. G. Oshima Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors Mol. Cell. Biol., December 1, 2003; 23(23): 8614 - 8625. [Abstract] [Full Text] [PDF]

				A. Agathanggelou, I. Bieche, J. Ahmed-Choudhury, B. Nicke, R. Dammann, S. Baksh, B. Gao, J. D. Minna, J. Downward, E. R. Maher, et al. Identification of Novel Gene Expression Targets for the Ras Association Domain Family 1 (RASSF1A) Tumor Suppressor Gene in Non-Small Cell Lung Cancer and Neuroblastoma Cancer Res., September 1, 2003; 63(17): 5344 - 5351. [Abstract] [Full Text] [PDF]

				N. Ohtani, P. Brennan, S. Gaubatz, E. Sanij, P. Hertzog, E. Wolvetang, J. Ghysdael, M. Rowe, and E. Hara Epstein-Barr virus LMP1 blocks p16INK4a-RB pathway by promoting nuclear export of E2F4/5 J. Cell Biol., July 21, 2003; 162(2): 173 - 183. [Abstract] [Full Text] [PDF]

				E.J. Wolvetang, T.J. Wilson, E. Sanij, J. Busciglio, T. Hatzistavrou, A. Seth, P.J. Hertzog, and I. Kola ETS2 overexpression in transgenic models and in Down syndrome predisposes to apoptosis via the p53 pathway Hum. Mol. Genet., February 1, 2003; 12(3): 247 - 255. [Abstract] [Full Text] [PDF]

				N. Neznanov, L. Neznanova, R. V. Kondratov, L. Burdelya, E. S. Kandel, D. M. O'Rourke, A. Ullrich, and A. V. Gudkov Dominant Negative Form of Signal-regulatory Protein-alpha (SIRPalpha /SHPS-1) Inhibits Tumor Necrosis Factor-mediated Apoptosis by Activation of NF-kappa B J. Biol. Chem., January 31, 2003; 278(6): 3809 - 3815. [Abstract] [Full Text] [PDF]

				Y. Seki, M. A. Suico, A. Uto, A. Hisatsune, T. Shuto, Y. Isohama, and H. Kai The ETS Transcription Factor MEF Is a Candidate Tumor Suppressor Gene on the X Chromosome Cancer Res., November 15, 2002; 62(22): 6579 - 6586. [Abstract] [Full Text] [PDF]

				F. de Nigris, T. Mega, N. Berger, M. V. Barone, M. Santoro, G. Viglietto, P. Verde, and A. Fusco Induction of ETS-1 and ETS-2 Transcription Factors Is Required for Thyroid Cell Transformation Cancer Res., March 1, 2001; 61(5): 2267 - 2275. [Abstract] [Full Text]

				R. Fenrick, L. Wang, J. Nip, J. M. Amann, R. J. Rooney, J. Walker-Daniels, H. C. Crawford, D. L. Hulboy, M. S. Kinch, L. M. Matrisian, et al. TEL, a Putative Tumor Suppressor, Modulates Cell Growth and Cell Morphology of Ras-Transformed Cells While Repressing the Transcription of stromelysin-1 Mol. Cell. Biol., August 15, 2000; 20(16): 5828 - 5839. [Abstract] [Full Text]

				N. Neznanov, A. K. Man, H. Yamamoto, C. A. Hauser, R. D. Cardiff, and R. G. Oshima A Single Targeted Ets2 Allele Restricts Development of Mammary Tumors in Transgenic Mice Cancer Res., September 1, 1999; 59(17): 4242 - 4246. [Abstract] [Full Text] [PDF]

				L. le Gallic, D. Sgouras, G. Beal Jr., and G. Mavrothalassitis Transcriptional Repressor ERF Is a Ras/Mitogen-Activated Protein Kinase Target That Regulates Cellular Proliferation Mol. Cell. Biol., June 1, 1999; 19(6): 4121 - 4133. [Abstract] [Full Text] [PDF]

				G. Chen, M. Hitomi, J. Han, and D. W. Stacey The p38 Pathway Provides Negative Feedback for Ras Proliferative Signaling J. Biol. Chem., December 8, 2000; 275(50): 38973 - 38980. [Abstract] [Full Text] [PDF]

				A. Tugores, J. Le, I. Sorokina, A. J. Snijders, M. Duyao, P. S. Reddy, L. Carlee, M. Ronshaugen, A. Mushegian, T. Watanaskul, et al. The Epithelium-specific ETS Protein EHF/ESE-3 Is a Context-dependent Transcriptional Repressor Downstream of MAPK Signaling Cascades J. Biol. Chem., June 1, 2001; 276(23): 20397 - 20406. [Abstract] [Full Text] [PDF]